A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) (MAESTRO-NAFLD-1)

Closed for enrollment

(956) 362-2378

Please contact us for more information or to learn if you are eligible to participate.

To evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching placebo

Principal Investigator	Fernando Membreno, MD
Co-PI	John Rodriguez
Sponsor	Madrigal Pharmaceuticals, Inc
Type of Trial	Interventional

5323 S. McColl Rd., Edinburg, TX 78539

(956) 362-2390